98 POSTER A Phase I study of sorafenib in combination with capecitabine in patients with advanced, solid tumors

Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

“…Dose-limiting toxicities at continuous doses higher than 400 mg bid were diarrhea, fatigue, and skin toxicity. [4][5][6][7] Preclinical studies in xenograft models (colon, breast, lung) showed that the primary effect of sorafenib was inhibition of tumor growth rather than tumor shrinkage. 3 These data suggested that, unlike cytotoxic agents, the primary clinical benefit of agents such as sorafenib may be disease stabilization.…”